RxDoctor Payments Data

Alyse Williams, MD

Family Medicine · Salt Lake City, UTNPI 1609280486

Payments from drug & device makers

$546in general payments, 2019–2025

Across 29 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$99
  • Novo Nordisk$89
  • Amgen$73
  • GSK$56
  • Teva Pharmaceuticals USA, Inc.$43
  • Takeda Pharmaceuticals U.S.A., Inc.$34
  • plus $151 from 7 others

What the payments were for

  • Food & beverage$546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$546 in reported general payments places this provider in the 55th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$9,046
Medicare patients
45
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban140$84,484
Spiriva RespimatTiotropium Bromide42$25,121
TrulicityDulaglutide30$24,553
JardianceEmpagliflozin29$24,193
OzempicSemaglutide24$23,600
MounjaroTirzepatide14$22,860
XareltoRivaroxaban21$21,682
VraylarCariprazine Hcl13$21,503
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,423
Tresiba Flextouch U-200Insulin Degludec11$14,572
Breo ElliptaFluticasone/Vilanterol25$11,620
Incruse ElliptaUmeclidinium Bromide22$8,172
Combivent RespimatIpratropium/Albuterol Sulfate15$7,899
Mesalamine16$6,501
Wixela InhubFluticasone Propion/Salmeterol30$5,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Jardiance, Combivent Respimat$21$57,21486 claims
Lilly USA, LLCTrulicity, Mounjaro$99$47,41344 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy$56$39,58778 claims
Novo NordiskOzempic$89$23,60024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 928 family medicine providers in Utah.

Other family medicine in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →